.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BK03_Empagliflozin.Empagliflozin .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BK03_Empagliflozin.Empagliflozin| name: | Empagliflozin |
| ATC code: | A10BK03 | route: | oral |
| n-compartments | 2 |
Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used primarily for the management of type 2 diabetes mellitus. It lowers blood glucose by increasing renal glucose excretion. Empagliflozin is approved and widely used in clinical practice, including for reduction of cardiovascular events in patients with type 2 diabetes and established cardiovascular disease.
Population pharmacokinetic model in healthy adult volunteers after oral administration; parameters apply to both male and female adults.
Riggs, MM, et al., & Macha, S (2013). Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes. Journal of clinical pharmacology 53(10) 1028–1038. DOI:10.1002/jcph.147 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23940010
Mondick, J, et al., & Nock, V (2018). Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus. Journal of clinical pharmacology 58(5) 640–649. DOI:10.1002/jcph.1051 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29251772
Munir, KM, & Davis, SN (2016). Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes. Clinical pharmacology : advances and applications 8 19–34. DOI:10.2147/CPAA.S77754 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27186083